Navigation Links
CryoCath Arctic Front(R) Results Published in JACC
Date:7/22/2008

ersistent AFib patients (n=53). Of the 1,403 pulmonary veins treated, 1,360 (or 97 percent) were ablated with Arctic Front or Arctic Front in combination with CryoCath's Freezor(R) MAX catheter demonstrating the broad applicability of Arctic Front cryoablation. The median number of applications per vein was 2.8 and the median total procedure time was 170 minutes confirming the ease of use and speed with which physicians are able to use Arctic Front compared with other ablation technologies.

The safety data reported in the article confirms the strong safety profile Arctic Front has demonstrated to date. There were no observed reports of atrio esophageal fistula, stroke, death or peri-interventional complications. Phrenic nerve palsies were reported in 7.5 percent of patients treated; in some instances these were resolved prior to the end of the procedure or hospital discharge and all cases were resolved by the 12-month follow up visit.

"This study demonstrates the utility of Arctic Front in effectively isolating the pulmonary veins, which is the clear strategy for treating paroxysmal AFib, and central strategy in treating persistent AFib," added Mr. Keltjens.

About Arctic Front

Arctic Front is a minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal Atrial Fibrillation. This bi-directional, double balloon catheter enables physicians to rapidly isolate all four pulmonary veins for the treatment of AFib. More than 2,600 patients have been treated in more than 45 centres across Europe.

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countri
'/>"/>

SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Echo Pharma Acquisition Limited ("Royalty ... Irish Takeover Rules (the "Announcement"), a firm intention to ... ELN ) to $12.50 per share in cash.  ... not conditional on due diligence.  The $1.00 per share ... reserved the right to waive down the Acceptance Threshold ...
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... -- Rhythm announced today the presentation of results from a ... symptoms among diabetic patients in the U.S. than previously ... with both type 1 and type 2 diabetes, but ... more common type 2 disease. ... of Medicine at Harvard Medical School and Director of ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
... This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic ... European industry experts at Pharma IQ,s to discuss FDA ... Over the last two years, the regulations have been ... there has been some confusion within the industry as ...
... 2011 Morphotek®, Inc., a subsidiary of Eisai ... assets relating to a proprietary tumor targeting platform ... payment and future development milestones. TMI, a biotechnology ... the tumor-targeting peptide (TTP) platform capable of delivering ...
Cached Medicine Technology:FDA to Address Industry Questions About Biosimilar Regulations at the Pharma's IQ Immunogenicity Event 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 2Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc. 3
(Date:5/20/2013)... Lansing, MI (PRWEB) May 20, ... Michigan Lupus Foundation will be ... meeting in Lansing on June ... Monday, June 10th, 6:30 p.m. ... Professional Building (Across from Sparrow ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Co-founder of ... will be a keynote speaker at the 5th International ... The conference brings together company representatives and independent ... trends in Internet marketing and investments. , The 2013 ... Inn Business Hotel México from May 20 to 21. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 The ... and community leaders behind bars for good at an ... 22 beginning at 9 a.m. , More than ... Executive Lock-Up to benefit individuals and families affected by ... including city officials, local celebrities, realtors, doctors, attorneys, bankers, ...
(Date:5/20/2013)... May 20, 2013 ... Who:    Sloan Gibson, President, USO and CEO ... of Outreach Initiatives and Partners, Sesame ... , Representatives from:,              ... • U.S. House ...
(Date:5/20/2013)... 20, 2013 National law firm Parker Waichman ... Law Firm P.A., both based in Little Rock, Arkansas – ... proposed $7.25 billion settlement of a price-fixing case against Visa ... was filed Wednesday, May 15, 2013, in the U.S. District ... lawsuit against Visa and MasterCard (Case No. 1:05-md-1720) is titled ...
Breaking Medicine News(10 mins):Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 2Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 3
... in the open access journal BMC Medicine has found that ... people in India are flawed and the actual number of ... who are from the Administrative Staff College of India, conducted ... of Medical Sciences in Hyderabad. ,According to ...
... to be merry, for Christmas is fast approaching. The Santa ... celebration, spreading cheer// all around, are observed to be grossly ... ,Doctors in Scotland have explained how most of the ... frightfully fat, and need to diet on a war footing. ...
... spiritual leader Sri Sri Ravi Shankar will set up ... an "amalgamation of science and spirituality". ,Yezdi Batliwala ... Trust, the educational wing of the Art of Living ... Tripathy, the secretary of the state's higher education department, ...
... from Quebec had a man made heart implanted inside ... who does not have a heart beat! ,“Heartmate II”, ... Cecere and Dr Nadia Giannetti in a three-hour surgery on Nov. ... decade. It works using a turbine balanced within a magnetic field. ...
... most often end up selling their homes according to a ... ,People diagnosed with cancer experience loss of income, ... at the same time face a number of extra costs, ... ,The Macmillan Cancer Support research indicated that almost 20% ...
... problems are not protected from attacks or stroke by taking ... ,Folic acid or folate is one of the B ... Some medical practitioners prescribe it to prevent cardiac problems. ... Public Health and Tropical Medicine, New Orleans led a research ...
Cached Medicine News:
XL STABI Hydrophilic Acrylic Lens....
XL OCTO Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
MemoryLens Prefolded Acrylic Lens....
Medicine Products: